Biomedical subjects
M N Silverstein
Publications and source records attributed to M N Silverstein.
Myeloproliferative diseases; their shifting spectrums.
Explore the source record for details and available documents.
Thymic anaerobic glycolytic rates in high-incidence and low-incidence leukemic mice.
Explore the source record for details and available documents.
Primary or hemorrhagic thrombocythemia.
Explore the source record for details and available documents.
Ruptured spleen in infectious mononucleosis.
Explore the source record for details and available documents.
The influence of tryptophan metabolites on tissue uptake of glucose.
Explore the source record for details and available documents.
Osteoarticular manifestations of Gaucher's disease.
Explore the source record for details and available documents.
The influence of combined glycolytic inhibitor, respiratory inhibitor, and protein antagonist on experimental tumor growth.
Explore the source record for details and available documents.
Splenectomy for agnogenic myeloid metaplasia.
Explore the source record for details and available documents.
Agnogenic myeloid metaplasia. Natural history and treatment.
Explore the source record for details and available documents.
Role of tryptophan metabolites in the hypoglycemia associated with neoplasia.
Explore the source record for details and available documents.
Anaerobic glycolysis in normal and leukemic bone-marrow leukocytes. Effect of methyl-glyoxal-bis-guanylhydrazone dihydrochloride.
Explore the source record for details and available documents.
Tryptophan metabolites in hypoglycemia associated with neoplasia.
Explore the source record for details and available documents.
The coexistence of myasthenia gravis and pernicious anemia.
Explore the source record for details and available documents.
Control of hypersplenism and painful splenomegaly in myeloid metaplasia by irradiation.
Explore the source record for details and available documents.
Pilot study of two adriamycin-based regimens in patients with advanced malignant lymphomas.
Forty-two patients with advanced malignant lymphomas, all of whom had failed at least one prior course of chemotherapy, were treated with one of two new combination chemotherapy regimens to determine patient tolerability. Twenty-seven patients received regimen 1, after which this study was discontinued, and subsequently 15 additional patients were treated with regimen 2. Regimen 1 (BAP) consisted of BCNU and adriamycin administered iv on Day 1 and prednisone administered orally on Days 1--5 with cycles repeated at 21-day intervals. Regimen 2 (VAP) consisted of VP-16-213 given iv on Days 1 and 2, adriamycin given iv on Day 3, and prednisone given on Days 3--7 in a schedule designed to produce cell cycle synchronization; cycles were repeated at 21--28-day intervals. Both regimens were, in general, well tolerated. Reversible bone marrow depression was the major toxic reaction observed. Nine of 27 patients treated with regimen 1 and five of 15 patients treated with regimen 2 experienced objective tumor regressions. Tolerable dosage levels of both regimens have been defined for future clincial trials.